Equities

Innovative Pharmaceutical Biotech Ltd

Innovative Pharmaceutical Biotech Ltd

Actions
  • Price (HKD)0.221
  • Today's Change-0.001 / -0.45%
  • Shares traded2.07m
  • 1 Year change-9.80%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in HKDIncome statement in HKDView more

Year on year Innovative Pharmaceutical Biotech Ltd has grown net income from a loss of 245.70m to a gain of 103.40m despite declining revenues.
Gross margin12.74%
Net profit margin1,497.15%
Operating margin4,805.16%
Return on assets7.13%
Return on equity--
Return on investment--
More ▼

Cash flow in HKDView more

In 2024, Innovative Pharmaceutical Biotech Ltd increased its cash reserves by 131.03%, or 1.74m. Cash Flow from Financing totalled 10.32m or 156.54% of revenues. In addition the company used 8.28m for operations while cash from investing was breakeven.
Cash flow per share0.0597
Price/Cash flow per share4.04
Book value per share-0.3549
Tangible book value per share-1.15
More ▼

Balance sheet in HKDView more

Innovative Pharmaceutical Biotech Ltd has a Debt to Total Capital ratio of 76.75%.
Current ratio0.025
Quick ratio--
Total debt/total equity--
Total debt/total capital0.7675
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.